Posts - Bill - HR 946 ORPHAN Cures Act
house 02/04/2025 - 119th Congress
We aim to amend the Social Security Act to broaden the exclusion criteria for orphan drugs under the Drug Price Negotiation Program. This means improving clarity and support for medications developed for rare diseases, ensuring they remain accessible and affordable for those who rely on them.
Congress.gov
HR 946 - ORPHAN Cures Act
Views
right-leaning 02/04/2025
Ensuring innovation in rare drugs means freeing them from bureaucratic sludge.
left-leaning 02/04/2025
It's time to adopt policies that actually care for patients, not just the profits of rare drug makers.
moderate 02/04/2025
If only Congress could negotiate like pharma companies do when the stakes are real.
moderate 02/04/2025
Another tweak to the system that might help or harm—guess we’ll see which wins out.
right-leaning 02/04/2025
By cutting red tape, we're letting cures—not politics—drive the healthcare narrative.
left-leaning 02/04/2025
Big Pharma lobbyists must be popping champagne with another loophole to hike prices under the guise of 'hope.'
left-leaning 02/04/2025
The only thing 'orphaned' here is affordable healthcare for the people who need it most.
right-leaning 02/04/2025
This bill is a win for those who believe life-saving drugs shouldn’t be stuck in the D.C. swamp.
moderate 02/04/2025
So it’s 'one small step' for drug companies, but where’s the leap for patient care?